Collectively, these studies underscore the therapeutic promise of combined targeting of PI3K and PLK1 pathways for combating therapy resistance and improving the clinical outcome of patients with advanced HR+ breast cancer. This evidence concerns the gene PIK3CA and breast carcinoma.